尿素治疗住院低钠血症的有效性与安全性
该研究回顾性分析了匹兹堡大学医学中心2016年7月至2017年8月间接受尿素治疗的住院低钠血症患者,发现尿素可有效升高血钠,且耐受性良好,无严重不良事件。
要点
- 尿素(7.5-90 g/d)治疗使血钠从124 mEq/L升至131 mEq/L(P<0.001)。
- 单用尿素组24小时血钠升幅大于未用尿素组(2.5 vs -0.5 mEq/L,P=0.04)。
- 无患者出现血钠纠正过快,无严重不良事件。
核心结论
- 尿素对住院低钠血症似乎有效且安全,耐受性良好。
主要发现
- 12例单用尿素患者血钠从125 mEq/L(IQR 122-127)升至131 mEq/L(IQR 129-136),P=0.001。
- 单用尿素组24小时血钠升幅2.5 mEq/L(IQR 0-4.5)高于未用尿素组-0.5 mEq/L(IQR -2.5至1.5),P=0.04。
- 治疗结束时血钠变化两组无差异(6 mEq/L [IQR 3.5-10] vs 5.5 mEq/L [IQR 3-7.5],P=0.51)。
- 单用尿素组达到正常血钠比例更高(33% vs 8%),但无统计学显著性(P=0.08)。
临床怎么用
- 尿素可作为住院低钠血症的治疗选择,需监测血钠变化。
局限性
- 回顾性研究,样本量较小,单用尿素组仅12例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Current therapies for hyponatremia have variable effectiveness and tolerability, and in certain instances, they are very expensive. We examined the effectiveness, safety, and tolerability of urea for the treatment of inpatient hyponatremia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We identified all patients hospitalized at the University of Pittsburgh Medical Center between July 2016 and August 2017 with hyponatremia (plasma sodium <135 mEq/L) who received urea, including a subgroup of patients who received urea as the sole drug therapy for hyponatremia (urea-only treated). We matched urea only-treated patients to a group of patients with hyponatremia who did not receive urea (urea untreated) and compared changes in plasma sodium at 24 hours and the end of therapy as well as the proportion of patients who achieved plasma sodium ≥135 mEq/L. We abstracted data on adverse events and reported side effects of urea. RESULTS: Fifty-eight patients received urea (7.5-90 g/d) over a median of 4.5 (interquartile range, 3-8) days and showed an increase in plasma sodium from 124 mEq/L (interquartile range, 122-126) to 131 mEq/L (interquartile range, 127-134; P<0.001). Among 12 urea only-treated patients, plasma sodium increased from 125 mEq/L (interquartile range, 122-127) to 131 mEq/L (interquartile range, 129-136; P=0.001) by the end of urea therapy. There was a larger increase in plasma sodium at 24 hours in urea only-treated patients compared with urea-untreated patients (2.5 mEq/L; interquartile range, 0-4.5 versus -0.5 mEq/L; interquartile range, -2.5 to 1.5; P=0.04), with no difference in change in plasma sodium by the end of therapy (6 mEq/L; interquartile range, 3.5-10 versus 5.5 mEq/L; interquartile range, 3-7.5; P=0.51). A greater proportion of urea only-treated patients achieved normonatremia, but this difference was not statistically significant (33% versus 8%; P=0.08). No patients experienced overly rapid correction of plasma sodium, and no serious adverse events were reported. CONCLUSIONS: Urea seems effective and safe for the treatment of inpatient hyponatremia, and it is well tolerated.
引用
- Rondon-Berrios H, Tandukar S, Mor MK, et al. Urea for the Treatment of Hyponatremia. Clin J Am Soc Nephrol. 2018. PMID: 30181129. doi:10.2215/CJN.04020318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。